3823-19-6

Basic information

• Product Name: 2-BROMO-4-(TRIFLUOROMETHYL)ACETANILIDE
• Synonyms: BUTTPARK 76\07-26;4-ACETAMIDO-3-BROMOBENZOTRIFLUORIDE;2'-BROMO-4'-(TRIFLUOROMETHYL)ACETANILIDE;2-BROMO-4-(TRIFLUOROMETHYL)ACETANILIDE;N1-[2-BROMO-4-(TRIFLUOROMETHYL)PHENYL]ACETAMIDE;N-(Bromoacetyl)-4-(trifluoromethyl)aniline;4-(trifluoromethyl)-alpha-bromo-acetanilide;N-(2-Bromo-4-(trifluoromethyl)phenyl)acetamide
• CAS NO: 3823-19-6
• Molecular Formula: C₉H₇BrF₃NO
• Molecular Weight: 282.06
• Product Categories: Amines;blocks;Bromides;FluoroCompounds
• Mol File: 3823-19-6.mol
• Article Data: 12

Chemical Properties

• Melting Point: 144-146°C
• Boiling Point: 324.2 °C at 760 mmHg
• Flash Point: 149.9 °C
• Appearance: /
• Density: 1.666g/cm³
• Vapor Pressure: 5.7E-05mmHg at 25°C
• Refractive Index: 1.541
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.81±0.70(Predicted)
• CAS DataBase Reference: 2-BROMO-4-(TRIFLUOROMETHYL)ACETANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-4-(TRIFLUOROMETHYL)ACETANILIDE(3823-19-6)
• EPA Substance Registry System: 2-BROMO-4-(TRIFLUOROMETHYL)ACETANILIDE(3823-19-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 3823-19-6(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-(Trifluoromethyl)acetanilide is a chemical compound often used in organic synthesis processes. It has a molecular formula of C9H6BrF3NO and a molar mass of 292.05 g/mol. The compound is generally characterized by its aromatic ring structure, the presence of a bromine (Br) atom, a trifluoromethyl (CF3) group, and an acetanilide group. This contributes to its reactivity and its utility in the synthesis of various organic compounds. Additionally, the chemical is generally produced and used under controlled laboratory conditions, indicating its significance in chemical research areas. Little is known about its toxicity or environmental impact. It should nonetheless be handled with proper safety measures due to potential unknown risks.

InChI:InChI=1/C9H7BrF3NO/c10-5-8(15)14-7-3-1-6(2-4-7)9(11,12)13/h1-4H,5H2,(H,14,15)

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 455-14-1 4-trifluoromethylphenylamine 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 1245749-11-4 C₁₉H₁₃F₃N₄OS 

Relevant articles and documents

Synthesis and Cytotoxic Evaluation of Some New 1,2,3-Triazole Linked 2-Imino-4-(Trifuoromethyl)-Thiazolidin-4-ol Derivatives

A new series of 1,2,3-triazole tagged 2-imino-4-(trifluoromethyl)thiazolidinol derivatives was synthesized through click chemistry under Sharpless conditions and evaluated for anticancer activity against human monocytic leukemia (U937), human breast adeno

5-[2-(N-(Substituted phenyl)acetamide)]amino-1,3,4-thiadiazole-2-sulfonamides as Selective Carbonic Anhydrase II Inhibitors with Neuroprotective Effects

In this study, 22 novel compounds were designed and synthesized by acetamide bridge chains, among which 5 a–5 k were monosubstituted compounds, and 6 a–6 k were disubstituted. A series of biological evaluations was then carried out to determine the carbonic anhydrase inhibitory activity, neuroprotective effects and cytotoxicity of 5 a–5 k and 6 a–6 k. The results showed that some compounds could protect PC12 cells from sodium nitroprusside (SNP)-induced damage. In terms of the neuroprotection and inhibitory activity against carbonic anhydrase II, monosubstituted compounds were better than disubstituted. Compound 5 c exhibited better protective effect in PC12 cells than that of edaravone, and 5 c also showed less cytotoxicity. In addition, compound 5 c was found to be the most effective selective carbonic anhydrase II inhibitor (IC50=16.7 nM, CAI/CAII=54.3), which was similar to the inhibitory effect of acetazolamide. Moreover, the selectivity of compound 5 c was better than that of acetazolamide (IC50=12.0 nM, CAI/CAII=20.8). Molecular docking presented that the binding effect of compound 5 c with carbonic anhydrase II was superior to that of 5 c with carbonic anhydrase I and IX, which was consistent with the inhibitory results. Based on above findings, compound 5 c may be a potential candidate for selective carbonic anhydrase II inhibitor, and it had obviously neuroprotective effect and great advantages in drug safety.

Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs

A novel series of acetamide-substituted derivatives and two prodrugs of doravirine were designed and synthesized as potent HIV-1 NNRTIs by employing the structure-based drug design strategy. In MT-4 cell-based assays using the MTT method, it was found that most of the new compounds exhibited moderate to excellent inhibitory potency against the wild-type (WT) HIV-1 strain with a minimum EC50 value of 54.8 nM. Among them, the two most potent compounds 8i (EC50 = 59.5 nM) and 8k (EC50 = 54.8 nM) displayed robust activity against WT HIV-1 with double-digit nanomolar EC50 values, being superior to lamivudine (3TC, EC50 = 12.8 μM) and comparable to doravirine (EC50 = 13 nM). Besides, 8i and 8k shown moderate activity against the double RT mutant (K103N + Y181C) HIV-1 RES056 strain. The HIV-1 RT inhibition assay further validated the binding target. Molecular simulation of the representative compounds was employed to provide insight on their structure-activity relationships (SARs) and direct future design efforts. Finally, the aqueous solubility and chemical stability of the prodrugs 9 and 10 were investigated in detail.